Advocacy intelligence hub — real-time data for patient organizations
REBINYN: FDA approved
Routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital Factor IX deficiency)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
REBINYN
Novo Nordisk
REBINYN
(COAGULATION FACTOR IX RECOMBINANT, GLYCOPEGYLATED)Orphan drugNovo Nordisk